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Introduction
There is a great need for better preclinical methodology to study drug effects on cancers in 3-dimensional growth. Because anchorage-independent growth, or the cell's ability to proliferate without being attached to or spreading onto a substratum, is one of the hallmarks of transformation and the most accurate in vitro indication of tumorgenicity, it is the criterion used most commonly to validate oncology targets and the one we used in the present study.
To evaluate our new methodology we chose three drugs with differing modes of action. One drug is alpha-difluoromethylornithine (DFMO, eflornithine), a drug that irreversibly inactivates the enzyme L-ornithine decarboxylase (ODC) that converts ornithine to the polyamine putrescine. The importance of this activity stems from the fact that polyamines have essential roles in DNA synthesis, transcription, and protein synthesis and are believed to participate in cellular The second agent is carboplatin, a platinum-based compound that binds to DNA and interferes with cell division. Carboplatin is used in the treatment of in vitro studies of combination therapy consisting of cisplatin and DFMO have shown either an antagonistic (7) (8) (9) (10) (11) or an additive/synergistic (12-14) effect of the two on the growth of tumor cell lines.
The third agent is suberoyl-anilide hydroxamic acid (SAHA, vorinostat), a histone deacetylase (HDAC) inhibitor that inhibits all class I and II HDACs and induces growth arrest, differentiation, and/or apoptosis of transformed cells in vitro and inhibits tumor growth in vivo (15) (16) (17) (18) (19) . These new class of chemotherapeutic agents that target the cell cycle checkpoint and chromatin structure that can be altered during tumorigenesis. HDAC inhibitors have shown significant promise in the treatment of a variety of cancers in clinical trials (20, 21) .
With the increasing emphasis on combination treatment for cancers, especially gliomas, and the increasing number of agents under development for the treatment of gliomas, it is important to have a reproducible and easy-to-perform quantitative 3D assay that can fully reflect the drug effect on both colony size and number; this assay would also be useful for identifying new drug combinations. Currently, traditional colony assays are used for this purpose, but these rely on staining and the visual recognition of colony size and number and are not sufficiently precise and practical for testing. With this goal in mind, we have developed a 3D agarose colony formation assay using GelCount™, a new cell colony counter for gels and soft agars. GelCount™ scans culture plates, counts colonies, and measures the diameter (μm) and density (OD) of the 3D colonies. The GelCount™ apparatus also allows repetitive plate counting over time and under different conditions without staining cells. We also sought to be as quantitative as possible in our determination of the effect of the drug(s) on differential colony formation. Toward that end, we used a range of five cell lines that included both gliomas and adenocarcinomas. We also followed the effects of drug treatment on all colonies over time.
Materials and Methods

Cell Lines and Culture Conditions
We used SNB19, U251MG, and LNZ308 glioma cell lines and MiaPaCa pancreas and SW480 colon adenocarcinoma cell lines. Our choice of cell lines was based partly on their disparate levels of ODC and sensitivity to DFMO. They were maintained in ATCC-recommended media supplemented with 10% fetal calf serum and 1% penicillin/streptomycin in a humidified atmosphere of 95% air/5% carbon dioxide at 37 ºC. Glioma cell lines were maintained in Dulbecco's modified essential/F12 medium supplemented with 5% fetal bovine serum (FBS). MiaPiaCa and SW480 cells were maintained in Leibovitz's L-15 medium supplemented with 5% FBS. Cells were harvested with trypsin/ethylenediamine tetraacetic acid solution, rinsed twice with Ca 2+ -and Mg 2+free PBS, and resuspended to yield a final concentration of 1200 cells/1.0 ml of matrix volume.
Drugs
We studied DFMO, carboplatin, and SAHA, an HDAC inhibitor, over a 3-log dose range, both as single agents and in combination. DFMO, with a molecular weight of 237, was a gift of Patrick Woster (Wayne State University, Detroit, MI). Carboplatin (cis-diammine-1,1-cyclobutanedicarboxylate platinum II; CBDCA) was purchased from SIGMA-ALDRICH (St. Louis, MO). SAHA (vorinostat) was a gift of William Bornmann (The University of Texas M. D. Anderson Cancer Center).
DFMO and carboplatin were dissolved in pyrogen-free water or culture medium. SAHA was dissolved in dimethylsulfoxide and stored as 10 mM (2.643 mg/ml) stock solutions at -80 ºC.
3D Agarose Colony Formation Assay
A total of 1200 cells/well of a 12-well plate were used. Cells were suspended in a 1.0 ml volume, 70% of which was medium without phenol red, 13% of which was fetal calf serum, and 17% of which was 0.5% agarose (Fisher Scientific, Austin, TX). This suspension was overlaid on a solidified 1.0 ml base matrix, 70% of which medium, 13% of which was fetal calf serum, and 17% of which was 0.7% agarose. An additional 0.8 ml of medium was layered over this cell matrix. After 3-15 days, colonies were counted using the GelCount™ technology (Oxford Optronix Inc., Oxford, United Kingdom), a relatively new cell colony counter for gel and soft agar 3D assays. The GelCount™ scan and image acquisition are operational using a Microsoft Windows-based program. GelCount™ software was developed by Oxford Optronix, Inc.
Clonogenic Assay
Day 1: Making the Assay: All assays were performed in triplicate using non-tissue culture (TC) treated 22 mm culture wells. Cells (1,200 cells) were suspended in a 1.0 ml volume, 70% of with respect to dose and time which was medium, 13% of which was fetal calf serum, and 17% of which was 0.5% agarose (Fisher Scientific, Austin, TX). This suspension was layered over a solidified 1.0 ml matrix, 70% of which was medium, 13% of which was fetal calf serum, and 17% of which was 0.7% agarose. An additional 0.4 ml of media was layered over this cell matrix. Matrices formed as gels in <20 minutes.
Day 8 (Glioma Cells) or Day 4 (Adenocarcinoma Cells):
After a 5-day equilibration period, the drug dissolved in 0.2 ml of medium was sterile filtered using a 0.2 μm mesh filter and mixed proportionally with medium to achieve 3-fold doses. The 2.4 ml working volume was taken into account during calculations. Control wells received 0.2 ml of medium alone.
Day 8-15 (Glioma Cells) or Day 4-11 (Adenocarcinoma Cells): Imaging and Counting. Because the growth rate of control colonies varied among cell lines, images were obtained between days 11-15 using GelCount™.
Analysis of the GelCount™ Data
GelCount™ scans of the 3D colonies yielded outputs to Microsoft Excel files regarding five parameters: measured diameter (d, μm), measured optical density (OD), calculated area (A), calculated volume (V), and the distance of the nearest neighbor colony (μm). Where,
From these measures, we approximated the area under the colony size curve (AUC) as the sum of colony volumes in each plate as,
These data were then used to calculate IC 50 values using Prism 5 software (GraphPad; San Diego, CA) and the log dose inhibition algorithm where X = log dose and Y, Bottom, and Top are all Total Volume in units μm 2 OD and the graph is fit to the equation:
Results
Set Up of GelCount™
We carefully cleaned the plates with 80% alcohol before counting and manually deleted dust manually after count- ing. GelCount™ can scan plates at 300, 600, 1200, or 2400 dpi and counts the signals on the scanning image. We found that 2400 dpi images were very clear and detected the most signals; however, even when we could not find colonies or dust images at this resolution, there were many unknown artifact signals. As a result, we decided to use 1200 dpi, which does not show many artifacts, even though there are some uncounted signals because of the lower resolution.
3D Agarose Colony Formation in 12-well Plates
To confirm the GelCount™ properties and the characteristics of the cell lines, we made 3D agarose colony plates using SNB19, LNZ308, and U251MG glioma cells and MiaPaCa pancreas and SW480 colon adenoma cell lines. We spread 1200 cells in one well of a 12-well plate and counted cells 3-15 days later using GelCount™. The number of days it took for colonies to be detected depended on the cell line ( Figure 1A-1C) . Figure 1A is a plot of the colony number vs. the day of the GelCount™ scan; Figure 1B is a plot of the average colony volume vs. the day of the GelCount™ scan; and Figure 1C is a plot of the total volume (A × OD) of colonies vs. the day of the Gel Count™ scan. From this, it can be appreciated that adenocarcinoma colonies grew very fast. Specifically, GelCount™ began to count adenocarcinoma colonies starting at 3-4 days, with over 100 colonies forming by 5-6 days. In fact, MiaPaCa colonies grew so fast that some colonies overlapped other colonies. Furthermore, large monolayer colonies grew in the bottom of the plate and/or between the top and base agarose. These monolayer colonies and overlapping colonies resulted in a significant increase in the number of artifacts and in sample-to-sample variation. Therefore, MiaPaCa cells were not incubated for longer than 10 days in subsequent studies. On the other hand, glioma colonies were slower to form than adenocarcinoma cell lines. Specifically, it took 6 to 7 days to detect glioma colonies and 9-10 days for over 100 colonies to form. As a result, incubation done within 2 weeks was adequate for glioma cell lines.
Single-Drug Colony Assay
A single-drug colony assay was performed to assess the time course of the growth suppression of each colony after the addition of drugs and to determine the IC 50 dose of each drug. dose-dependent manner. Indeed, the expanding gap in the number of colonies detected and their size in response to the maximum and minimum doses were remarkably different.
Based on curves such as those in Figures 2-4 and using a log dose inhibition algorithm, we computed IC 50 values on days 3, 5, 7, and 9 after drug exposure. These values are summarized in Table II . Since the curves and fits were best on days 7 and 9, we used an average value of the values from days 7 and 9 as the experimental IC 50 for future studies. As expected, the IC 50 for each drug varied by cell line. For DFMO, the range was 37 to 353 μM and the order for increasing IC 50 was MiaPiaCa > LNZ308 > Sw480 > U251MG > SNB19. For carboplatin, the range was much narrower at 2.5 to 8.6 μM and the order for increasing IC 50 was less demarcated, with SNB19 ~ U251MG > LNZ308 ~ SW480 > MiaPiaCa. For SAHA, the IC 50 range was also narrow and at between 1.0 to 2.8 μM and the order of cell lines poorly demarcated, with LNZ308 ~ MiaPiaCa > SW480 ~ SNB19 > U251MG.
Discussion
We believe that we have accomplished our study goal of establishing a reproducible and easy-to-perform quantitative 3D assay that can fully reflect drug action on both colony size and number. Unique to our assay methodology, which A
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Log ( relies on the newly available GelCount™ imaging system, is the application of the AUC to render a combined reading of the size and frequency of colonies. Using this methodology we were able to reliably determine IC 50 values for three anticancer drugs against five different cell lines.
Many laboratories use colony formation assays for investigating the effect of anticancer drugs, radiation, and forced gene expression. However, a problem with this approach is that most assays used are two-dimensional. In a living body, tumor growth occurs in three dimensions; that is, it involves anchorage-independent growth, which is actually one of the most important measures of tumorgenicity. Of further concern, the primary experimental method for assessing anchorage-independent growth is soft agar (agarose) colony formation, which measures cell proliferation through the manual counting of colonies in semisolid culture media. While this assay is effective, it has many problems. For example, a large number of culture plates are needed for the assay, and it can take quite a while to perform the assay. In addition, the counting of colonies by eye is subject to bias, and colony size is difficult, if not impossible, to determine meaningfully. The 6-or 12-well soft agar assay done using Gel Count™ technology we describe here circumvents these problems.
Its major advantage is that the culture plate can be scanned repeatedly without cell staining and without damaging the colonies. This makes it possible for true growth curves and time-dependent effects to be quantified using colony number and colony size (area or volume). In addition, the method we developed is reproducible and more quantitative than traditional colony assays that rely on staining and the visual recognition of colony size and number and more robust, since it allows repetitive measurements of colony size without the need for staining and/or the inactivation of colony growth.
